MY169028A - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents
Process for making hydroxylated cyclopentylpyrimidine compoundsInfo
- Publication number
- MY169028A MY169028A MYPI2014703415A MYPI2014703415A MY169028A MY 169028 A MY169028 A MY 169028A MY PI2014703415 A MYPI2014703415 A MY PI2014703415A MY PI2014703415 A MYPI2014703415 A MY PI2014703415A MY 169028 A MY169028 A MY 169028A
- Authority
- MY
- Malaysia
- Prior art keywords
- compounds
- making
- making hydroxylated
- cyclopentylpyrimidine compounds
- hydroxylated cyclopentylpyrimidine
- Prior art date
Links
- KHXLVDUXFUNEQQ-UHFFFAOYSA-N 2-cyclopentylpyrimidine Chemical class C1CCCC1C1=NC=CC=N1 KHXLVDUXFUNEQQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648473P | 2012-05-17 | 2012-05-17 | |
| US201361785122P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY169028A true MY169028A (en) | 2019-02-04 |
Family
ID=48485537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014703415A MY169028A (en) | 2012-05-17 | 2013-05-17 | Process for making hydroxylated cyclopentylpyrimidine compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9416110B2 (enExample) |
| EP (1) | EP2861582B1 (enExample) |
| JP (1) | JP6284928B2 (enExample) |
| KR (1) | KR102067850B1 (enExample) |
| CN (1) | CN104470913B (enExample) |
| AU (1) | AU2013262505B2 (enExample) |
| BR (1) | BR112014028589B1 (enExample) |
| CA (1) | CA2873654C (enExample) |
| DK (1) | DK2861582T3 (enExample) |
| ES (1) | ES2582557T3 (enExample) |
| IL (1) | IL235715A (enExample) |
| MX (1) | MX353384B (enExample) |
| MY (1) | MY169028A (enExample) |
| NZ (1) | NZ702935A (enExample) |
| PL (1) | PL2861582T3 (enExample) |
| RU (1) | RU2643811C2 (enExample) |
| SG (1) | SG11201407616TA (enExample) |
| SI (1) | SI2861582T1 (enExample) |
| WO (1) | WO2013173768A1 (enExample) |
| ZA (1) | ZA201409261B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173736A1 (en) | 2012-05-17 | 2013-11-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| PE20150725A1 (es) | 2012-05-17 | 2015-05-17 | Genentech Inc | Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| CA2873654C (en) | 2012-05-17 | 2021-06-22 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| ES2957314T3 (es) | 2013-11-15 | 2024-01-17 | Hoffmann La Roche | Procesos para la preparación de compuestos de pirimidinilciclopentano |
| SG11201702324QA (en) * | 2014-09-26 | 2017-04-27 | Hoffmann La Roche | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS |
| CN109789141B (zh) | 2016-08-10 | 2022-08-26 | 豪夫迈·罗氏有限公司 | 包含Akt蛋白激酶抑制剂的药物组合物 |
| MX2022015322A (es) | 2020-06-16 | 2023-01-11 | Hoffmann La Roche | Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada. |
| KR102689151B1 (ko) * | 2021-09-06 | 2024-07-29 | 연세대학교 산학협력단 | Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134212C (zh) | 1993-12-12 | 2004-01-14 | 阿格罗吉恩有限公司 | 保护植物免受真菌侵染的新方法 |
| AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
| US6376496B1 (en) | 1999-03-03 | 2002-04-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CN1281604C (zh) * | 1999-06-03 | 2006-10-25 | 帝国脏器制药株式会社 | 取代吡唑化合物 |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| WO2004108673A2 (en) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibitors of papilloma virus |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| CA2758484A1 (en) | 2009-04-15 | 2010-10-21 | David A. Degoey | Anti-viral compounds |
| JP5581390B2 (ja) * | 2009-10-23 | 2014-08-27 | イーライ リリー アンド カンパニー | Ａｋｔ阻害剤 |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| WO2012177925A1 (en) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| PE20150725A1 (es) | 2012-05-17 | 2015-05-17 | Genentech Inc | Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este |
| CA2873658C (en) | 2012-05-17 | 2021-01-26 | Genentech, Inc. | Process for making amino acid compounds |
| CA2873654C (en) | 2012-05-17 | 2021-06-22 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| WO2013173736A1 (en) | 2012-05-17 | 2013-11-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| US20140121193A1 (en) | 2012-11-01 | 2014-05-01 | Robert S. Katz | Methods for treating fibromyalgia |
| EP2956441A4 (en) | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
| US10131637B2 (en) | 2013-03-15 | 2018-11-20 | Shifa Biomedical Corporation | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
-
2013
- 2013-05-17 CA CA2873654A patent/CA2873654C/en active Active
- 2013-05-17 DK DK13725042.9T patent/DK2861582T3/en active
- 2013-05-17 RU RU2014151050A patent/RU2643811C2/ru active
- 2013-05-17 US US14/401,087 patent/US9416110B2/en active Active
- 2013-05-17 BR BR112014028589-6A patent/BR112014028589B1/pt active IP Right Grant
- 2013-05-17 JP JP2015512900A patent/JP6284928B2/ja active Active
- 2013-05-17 MY MYPI2014703415A patent/MY169028A/en unknown
- 2013-05-17 PL PL13725042.9T patent/PL2861582T3/pl unknown
- 2013-05-17 MX MX2014013862A patent/MX353384B/es active IP Right Grant
- 2013-05-17 SI SI201330261A patent/SI2861582T1/sl unknown
- 2013-05-17 KR KR1020147035427A patent/KR102067850B1/ko active Active
- 2013-05-17 ES ES13725042.9T patent/ES2582557T3/es active Active
- 2013-05-17 AU AU2013262505A patent/AU2013262505B2/en active Active
- 2013-05-17 EP EP13725042.9A patent/EP2861582B1/en active Active
- 2013-05-17 SG SG11201407616TA patent/SG11201407616TA/en unknown
- 2013-05-17 NZ NZ702935A patent/NZ702935A/en not_active IP Right Cessation
- 2013-05-17 CN CN201380038057.4A patent/CN104470913B/zh active Active
- 2013-05-17 WO PCT/US2013/041666 patent/WO2013173768A1/en not_active Ceased
-
2014
- 2014-11-13 IL IL235715A patent/IL235715A/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09261A patent/ZA201409261B/en unknown
-
2016
- 2016-07-07 US US15/204,715 patent/US9676730B2/en active Active
-
2017
- 2017-05-11 US US15/593,064 patent/US9790190B2/en active Active
- 2017-10-12 US US15/782,620 patent/US20180258054A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY169028A (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| NZ726356A (en) | Processes for preparing antiviral compounds | |
| IN2012DN02751A (enExample) | ||
| PH12018501094A1 (en) | Process for the preparation of an apoptosis-inducing agent | |
| MY199066A (en) | Processes for producing diazabicyclooctane compounds | |
| IN2014DN09053A (enExample) | ||
| IN2014DN00144A (enExample) | ||
| MX2013008371A (es) | Metodos para producir un compuesto profarmaco inhibidor de la union al virus de inmunodeficiencia humana e intermediarios. | |
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| MX2015013589A (es) | Proceso e intermediario para la preparacion de pregabalina. | |
| IN2014DN06192A (enExample) | ||
| WO2012140490A3 (en) | Processes for preparing pitavastatin calcium | |
| EA201491446A1 (ru) | Способы получения пиперазинового пролекарства - ингибитора прикрепления вич | |
| IN2014MU01192A (enExample) | ||
| MX2016007186A (es) | Nuevo procedimiento de sintesis de la agomelatina. | |
| IN2014MU00195A (enExample) | ||
| MY174153A (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
| IN2014DN07162A (enExample) | ||
| IN2012DN02000A (enExample) | ||
| WO2013072936A3 (en) | A novel process for the preparation of (r)-n-benzyl-2 acetamido-3-methoxypropionamide | |
| IN2014MU00194A (enExample) | ||
| IN2014MU01196A (enExample) | ||
| MX2014012822A (es) | Proceso para elaborar derivados de naftiridina. | |
| MY161361A (en) | Substituted phenyl compounds | |
| MX2015017747A (es) | Proceso para producir 2-fenil-1, 3-benzoxazoles. |